Antibiotics for the treatment of COVID-19-Reference-Cited by-同舟云学术

Antibiotics for the treatment of COVID-19

Published:2021-10-22 Issue:10 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Popp Maria¹,Stegemann Miriam²,Riemer Manuel¹,Metzendorf Maria-Inti³,Romero Carolina S⁴,Mikolajewska Agata²,Kranke Peter¹,Meybohm Patrick¹,Skoetz Nicole⁵,Weibel Stephanie¹

Affiliation:

1. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital Wuerzburg; Wuerzburg Germany

2. Department of Infectious Diseases and Respiratory Medicine; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Germany

3. Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf; Düsseldorf Germany

4. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; General University Hospital Valencia; Valencia Spain

5. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference222 articles.

1. Cavalcanti AB Zampieri FG Azevedo LC Rosa RG Avezum A Veiga VC Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial medrxiv.org/content/10.1101/2020.05.19.20106997v1

2. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19;Cavalcanti;New England Journal of Medicine ,2020

3. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I) clinicaltrials.gov/ct2/show/NCT04322123

4. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease clinicaltrials.gov/ct2/show/results/NCT04358081?view=results

5. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial;Furtado;Lancet,2020

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe COVID-19 infection: An institutional review and literature overview;PLOS ONE;2024-08-20

2. Impact of the COVID-19 pandemic on the utilisation and quality of antibiotic use in the Scottish primary care setting: a population-based segmented interrupted time-series analysis;Expert Review of Anti-infective Therapy;2024-06-14

3. Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model;Cardiovascular Toxicology;2024-06-08

4. Impacts of Comorbidity and Mental Shock on Organic Micropollutants in Surface Water During and After the First Wave of COVID-19 Pandemic in Wuhan (2019–2021), China;Engineering;2024-06

5. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan;Nature Communications;2024-05-27